IA
BIIB icon

Icon Advisers’s Biogen BIIB Stock Holding History

Icon Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,700
Closed -$1.78M – 356
2017
Q3 		$1.78M Buy
+5,700
New +$1.69M 0.13% 200
2016
Q1 		– Sell
-42,800
Closed -$13.1M – 340
2015
Q4 		$13.1M Sell
42,800
-15,960
-27% -$4.59M 0.9% 20
2015
Q3 		$17.1M Sell
58,760
-7,810
-12% -$2.58M 1.18% 9
2015
Q2 		$26.9M Sell
66,570
-250
-0.4% -$100K 1.69% 3
2015
Q1 		$28.2M Sell
66,820
-9,180
-12% -$3.62M 1.65% 4
2014
Q4 		$25.8M Buy
76,000
+14,740
+24% +$4.77M 1.53% 7
2014
Q3 		$20.3M Buy
61,260
+25,800
+73% +$8.51M 1.18% 20
2014
Q2 		$11.2M Buy
35,460
+23,100
+187% +$6.95M 0.7% 37
2014
Q1 		$3.78M Sell
12,360
-26,640
-68% -$8.46M 0.27% 93
2013
Q4 		$10.9M Buy
39,000
+13,900
+55% +$3.6M 0.79% 30
2013
Q3 		$6.04M Hold
25,100
– – 0.46% 51
2013
Q2 		$5.4M Buy
+25,100
New +$5.36M 0.42% 57

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Icon Advisers's BIIB Position: Q4 2017 in Review

Icon Advisers sold out of Biogen (BIIB) in Q4 2017, closing a stake of 5,700 shares — an estimated $1.78M sold.

Icon Advisers first reported a position in BIIB in Q2 2013 and held it in 12 quarters. The position peaked at $28.2M in Q1 2015. 1,123 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

  • Icon Advisers reported no remaining Biogen position as of Q4 2017 after selling out during the quarter.
  • Icon Advisers sold 5,700 Biogen shares in Q4 2017, an estimated $1.78M.
  • Icon Advisers first reported a position in Biogen in Q2 2013 and held it in 12 quarters.
  • Icon Advisers's Biogen position peaked at $28.2M in Q1 2015.
  • 1,123 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on Icon Advisers's 13F filing for Q4 2017, filed 6 Feb 2018.